Olopatadine

Olopatadine
Clinical data
Trade names	Patanol, Pataday, Opatanol
AHFS/Drugs.com	Monograph
MedlinePlus	a602025
License data	US DailyMed: Olopatadine;
Pregnancy; category	AU: B1; ;
Routes of; administration	Eye drops, nasal spray
ATC code	S01GX09 (WHO) R01AC08 (WHO);
Legal status
Legal status	AU: S4 (Prescription only); UK: POM (Prescription only); US: ℞-only / OTC; EU: Rx-only;
Pharmacokinetic data
Elimination half-life	3 hours
Identifiers
	IUPAC name {(11Z)-11-[3-(dimethylamino)propylidene]-6,11-; dihydrodibenzo[b,e]oxepin-2-yl}acetic acid;
CAS Number	113806-05-6 ;
PubChem CID	5281071;
DrugBank	DB00768 ;
ChemSpider	4444528 ;
UNII	D27V6190PM;
KEGG	D08293 ; as HCl: D01192 ;
ChEMBL	ChEMBL1189432 ;
CompTox Dashboard (EPA)	DTXSID20150556 ;
Chemical and physical data
Formula	C21H23NO3
Molar mass	337.419 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(O)Cc2ccc1OCc3c(C(\c1c2)=C\CCN(C)C)cccc3;
	InChI InChI=1S/C21H23NO3/c1-22(2)11-5-8-18-17-7-4-3-6-16(17)14-25-20-10-9-15(12-19(18)20)13-21(23)24/h3-4,6-10,12H,5,11,13-14H2,1-2H3,(H,23,24)/b18-8- ; Key:JBIMVDZLSHOPLA-LSCVHKIXSA-N ;
	(what is this?) (verify)

Olopatadine, sold under the brand name Patanol among others, is an antihistamine medication used to decrease the symptoms of allergic conjunctivitis and allergic rhinitis (hay fever).^[2] It is used as eye drops or as a nasal spray.^[2] The eye drops generally result in an improvement within half an hour.^[2]

Common side effects include headache, sore throat, eye discomfort, or changes in perception of taste.^[3]^[2] More significant side effects may include sleepiness.^[2] It is unclear if use during pregnancy or breastfeeding is safe.^[4] It is an antihistamine and mast cell stabilizer.^[5]^[2]

Olopatadine was patented in 1986 and came into medical use in 1997.^[6] It is available as a generic medication.^[2] In 2021, it was the 263rd most commonly prescribed medication in the United States, with more than 1 million prescriptions.^[7]^[8]

^ "FDA Approves Three Drugs for Nonprescription Use Through Rx-to-OTC Switch Process". U.S. Food and Drug Administration (FDA). 14 February 2020. Archived from the original on 15 February 2020. Retrieved 14 February 2020. This article incorporates text from this source, which is in the public domain.
^ ^a ^b ^c ^d ^e ^f ^g "Olopatadine Hydrochloride Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Archived from the original on 27 March 2019. Retrieved 26 March 2019.
^ British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 1126. ISBN 9780857113382.
^ "Olopatadine ophthalmic Use During Pregnancy". Drugs.com. Archived from the original on 26 March 2019. Retrieved 26 March 2019.
^ Castillo M, Scott NW, Mustafa MZ, Mustafa MS, Azuara-Blanco A (June 2015). "Topical antihistamines and mast cell stabilisers for treating seasonal and perennial allergic conjunctivitis" (PDF). The Cochrane Database of Systematic Reviews. 2015 (6): CD009566. doi:10.1002/14651858.CD009566.pub2. hdl:2164/6048. PMC 10616535. PMID 26028608. Archived from the original on 28 August 2021. Retrieved 24 September 2019.
^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 549. ISBN 9783527607495. Archived from the original on 10 January 2023. Retrieved 20 September 2020.
^ "The Top 300 of 2021". ClinCalc. Archived from the original on 15 January 2024. Retrieved 14 January 2024.
^ "Olopatadine - Drug Usage Statistics". ClinCalc. Archived from the original on 8 July 2020. Retrieved 14 January 2024.

[FDA_switch-1] "FDA Approves Three Drugs for Nonprescription Use Through Rx-to-OTC Switch Process". U.S. Food and Drug Administration (FDA). 14 February 2020. Archived from the original on 15 February 2020. Retrieved 14 February 2020. This article incorporates text from this source, which is in the public domain.

[AHFS2019-2] ^ ^a ^b ^c ^d ^e ^f ^g "Olopatadine Hydrochloride Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Archived from the original on 27 March 2019. Retrieved 26 March 2019.

[BNF76-3] British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 1126. ISBN 9780857113382.

[4] "Olopatadine ophthalmic Use During Pregnancy". Drugs.com. Archived from the original on 26 March 2019. Retrieved 26 March 2019.

[Cas2015-5] Castillo M, Scott NW, Mustafa MZ, Mustafa MS, Azuara-Blanco A (June 2015). "Topical antihistamines and mast cell stabilisers for treating seasonal and perennial allergic conjunctivitis" (PDF). The Cochrane Database of Systematic Reviews. 2015 (6): CD009566. doi:10.1002/14651858.CD009566.pub2. hdl:2164/6048. PMC 10616535. PMID 26028608. Archived from the original on 28 August 2021. Retrieved 24 September 2019.

[Fis2006-6] Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 549. ISBN 9783527607495. Archived from the original on 10 January 2023. Retrieved 20 September 2020.

[7] "The Top 300 of 2021". ClinCalc. Archived from the original on 15 January 2024. Retrieved 14 January 2024.

[8] "Olopatadine - Drug Usage Statistics". ClinCalc. Archived from the original on 8 July 2020. Retrieved 14 January 2024.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]